Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Temozolomide in Advanced Uterine Leiomyosarcoma
NCT03880019Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and temozolomide in uterine leiomyosarcoma (uLMS), sponsored by National Cancer Institute. Primary endpoint: Confirmed Objective Response Rate at 6 months. Started Aug 2019; status: active, not recruiting.
02
Drugs
olaparibtemozolomide
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT03880019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03880019.